Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
P2Y1 CRISPR Activation Plasmid (h): sc-401759-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- P2Y1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- P2Y1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by P2Y1 CRISPR Activation Plasmid (h) and P2Y1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the P2RY1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: P2Y1 Antibody (E-1): sc-377324
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
P2Y1 CRISPR Activation Plasmid (h) | sc-401759-ACT | 20 µg | $397.00 |
P2RY1 encodes the human P2Y1 receptor, a G protein–coupled purinergic receptor activated primarily by extracellular ADP. P2Y1 couples to Gq/11 signaling to stimulate phospholipase C, elevate intracellular Ca2+, and engage PKC-dependent pathways that shape platelet activation, vascular tone, and secretory responses in multiple cell types. In the nervous and immune systems, P2Y1 contributes to neuromodulatory and inflammatory signaling through coordinated cross-talk with other purinergic receptors and downstream MAPK and calcium-dependent effectors. Dysregulated purinergic signaling involving P2Y1 has been studied in contexts including thrombosis-related biology, cardiovascular homeostasis, and neuroinflammation-associated phenotypes.
P2Y1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous P2RY1 expression without altering the underlying DNA sequence.
P2Y1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the P2RY1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the P2RY1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous P2Y1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native P2RY1 locus and enabling the study of P2Y1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of P2Y1 pathway restoration in tumor cells with silenced or reduced P2RY1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.